Detalhe da pesquisa
1.
Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial).
BMC Med Res Methodol
; 18(1): 125, 2018 11 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30400777
2.
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet Infect Dis
; 23(2): 183-195, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36272432
3.
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
Nat Commun
; 13(1): 7284, 2022 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36435798
4.
Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Health Technol Assess
; 24(47): 1-86, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32975189
5.
Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer.
Oncogene
; 24(7): 1212-9, 2005 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-15592519